Table 2.

Grade ≥3 adverse events, mortality, and doses of drug administered

Event (n = 17)N (%)
Febrile neutropenia9 (53%)
Sepsis3 (17%)
Esophagitis/ulcers2 (12%)
GIB2 (12%)
Hypotension2 (12%)
LFT elevation1 (6%)
Hypokalemia1 (6%)
Respiratory distress1 (6%)
Multi-organ failure1 (6%)
30-day mortality1 (6%)
60-day mortality1 (6%)
Total doses of ficlatuzumab administereda64
Delayed dosesb0 (0%)
Missed dosesc11 (16%)
  • NOTE: Date of censoring: June 30, 2020.

  • Abbreviation: LFT, liver function test.

  • aTotal doses of ficlatuzumab included four doses during induction per patient and any dose given as consolidation at the treating physician's discretion.

  • bDelayed doses only included induction (n = 68), since initiation of consolidation may be variable.

  • cMissed doses only accounted for dose during induction, since not all patients received ficlatuzumab consolidation.